{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:37:08Z","timestamp":1793659028089,"version":"4.5.1"},"publisher-location":"Cham","reference-count":39,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_6","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T16:25:48Z","timestamp":1533140748000},"page":"119-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Ruxolitinib"],"prefix":"10.1007","author":[{"given":"Stefanie","family":"Ajayi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"9","key":"6_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P et al (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101(9):1065\u20131073","journal-title":"Haematologica"},{"issue":"1","key":"6_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L et al (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225\u2013227","journal-title":"Leukemia"},{"issue":"13","key":"6_CR4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901","journal-title":"Blood"},{"issue":"22","key":"6_CR5","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood.V128.22.4246.4246","volume":"128","author":"N Daver","year":"2016","unstructured":"Daver N, Cortes JE, Pemmaraju N et al (2016) Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF). Blood 128(22):4246","journal-title":"Blood"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"848473","DOI":"10.1155\/2015\/848473","volume":"2015","author":"KL Davis","year":"2015","unstructured":"Davis KL, C\u00f4t\u00e9 I, Kaye JA et al (2015) Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol 2015:848473","journal-title":"Adv Hematol"},{"issue":"14","key":"6_CR7","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","volume":"123","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Biamonte F, Rotunno G et al (2014) Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 123(14):2157\u20132160","journal-title":"Blood"},{"issue":"9","key":"6_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"CN Harrison","year":"2012","unstructured":"Harrison CN, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798","journal-title":"N Engl J Med"},{"issue":"8","key":"6_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib versus best available therapy for myelofibrosis. Leukemia 30(8):1701\u20131707","journal-title":"Leukemia"},{"key":"6_CR10","doi-asserted-by":"crossref","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U et al (2017) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 20 Dec (epup ehead of print)","DOI":"10.1016\/S2352-3026(17)30237-5"},{"issue":"2","key":"6_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","volume":"41","author":"C Iancu-Rubin","year":"2013","unstructured":"Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R (2013) Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 41(2):155\u2013166","journal-title":"Exp Hematol"},{"key":"6_CR13","unstructured":"Jakavi\u00ae (2017) Summary of product characteristics, Novartis http:\/\/www.fachinfo.de . Last revised Apr 2017"},{"issue":"7037","key":"6_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144\u20131148","journal-title":"Nature"},{"key":"6_CR15","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Hoffman R, Talpaz M et al (2016) Results of the persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts <100,000\/\u00b5l. Blood 128(22):LBA-5","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5"},{"issue":"9","key":"6_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/jcmm.13095","volume":"21","author":"S McPherson","year":"2017","unstructured":"McPherson S, McMullin MF, Mills K (2017) Epigenetics in myeloproliferative neoplasms. J Cell Mol Med 21(9):1660\u20131667","journal-title":"J Cell Mol Med"},{"issue":"3","key":"6_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cell.2007.10.033","volume":"131","author":"C Mertens","year":"2007","unstructured":"Mertens C, Darnell JE Jr (2007) SnapShot: JAK-STAT signaling. Cell 131(3):612","journal-title":"Cell"},{"issue":"10","key":"6_CR18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V et al (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31(10):1285\u20131292","journal-title":"J Clin Oncol"},{"issue":"34","key":"6_CR19","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV et al (2017a) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850","journal-title":"J Clin Oncol"},{"key":"6_CR20","doi-asserted-by":"crossref","unstructured":"Mesa RA, Vannucchi AM, Mead A et al (2017b) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4(5):e225\u2013e236","DOI":"10.1016\/S2352-3026(17)30027-3"},{"issue":"1","key":"6_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399","journal-title":"Lancet Oncol"},{"issue":"6","key":"6_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R et al (2015) Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790\u2013797","journal-title":"Blood"},{"issue":"15","key":"6_CR23","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109\u20133117","journal-title":"Blood"},{"issue":"22","key":"6_CR24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V128.22.1124.1124","volume":"128","author":"RK Rampal","year":"2016","unstructured":"Rampal RK, Mascarenhas JO, Kosiorek HE et al (2016) Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and post-MPN AML: results of a phase I study (Myeloproliferative Disorders Research Consortium 109 trial). Blood 128(22):1124","journal-title":"Blood"},{"issue":"6","key":"6_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T et al (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809\u2013818","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"6_CR26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"AD Shilling","year":"2010","unstructured":"Shilling AD, Nedza FM, Emm T et al (2010) Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos 38(11):2023\u20132031","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"6_CR27","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M et al (2014) Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 123(24):3832\u20133842","journal-title":"Blood"},{"key":"6_CR28","doi-asserted-by":"crossref","unstructured":"Stegelmann F, Hebart H, Bangerter M et al (2016) Ruxolitinib plus pomalidomide in myelofibrosis: updated results from the Mpnsg-0212 Trial (NCT01644110). Blood 128(22):1939","DOI":"10.1182\/blood.V128.22.1939.1939"},{"issue":"1","key":"6_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L et al (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6(1):81","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12):1188\u20131191","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"6_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365(15):1455\u20131457","journal-title":"N Engl J Med"},{"issue":"5","key":"6_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435","journal-title":"N Engl J Med"},{"key":"6_CR33","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Bose P (2017) JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood 130(2):115\u2013125","DOI":"10.1182\/blood-2017-04-742288"},{"issue":"12","key":"6_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u20131127","journal-title":"N Engl J Med"},{"issue":"6","key":"6_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z et al (2012a) Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202\u20131209","journal-title":"Blood"},{"issue":"9","key":"6_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012b) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"4","key":"6_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol 161(4):508\u2013516","journal-title":"Br J Haematol"},{"issue":"1","key":"6_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 10(1):55","journal-title":"J Hematol Oncol."},{"issue":"22","key":"6_CR39","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017a) Acute graft-versus-host disease\u2014biologic process, prevention, and therapy. N Engl J Med 377(22):2167\u20132179","journal-title":"N Engl J Med"},{"issue":"26","key":"6_CR40","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017b) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579","journal-title":"N Engl J Med"},{"issue":"10","key":"6_CR41","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C et al (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062\u20132068","journal-title":"Leukemia"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T12:43:59Z","timestamp":1661690639000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":39,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_6","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}